Home » Synta Pharma Initiates Phase II Clinical Study of STA-9090
Synta Pharma Initiates Phase II Clinical Study of STA-9090
Synta Pharmaceuticals Corp said it is initiating a Phase 2 clinical study of STA-9090 in patients with advanced gastrointestinal stromal tumors, or GIST.
RTTNews
RTTNews
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May